Journal
JOURNAL OF RHEUMATOLOGY
Volume 39, Issue 8, Pages 1583-1602Publisher
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.120165
Keywords
RHEUMATOID ARTHRITIS; POSTMARKETING PRODUCT SURVEILLANCE; PRACTICE GUIDELINES; CONSENSUS DEVELOPMENT CONFERENCE; QUALITY OF HEALTHCARE
Categories
Funding
- Canadian Institutes of Health Research
- Canadian Rheumatology Association
- UCB/CRA/TAS Post-Graduate Rheumatology Fellowship
- Alberta Innovates Health Solutions Clinical Fellowship
- Fonds de la Recherche en Sante de Quebec (FRSQ)-Doctoral Research Award
Ask authors/readers for more resources
Objective. The Canadian Rheumatology Association (CRA) has developed recommendations for the pharmacological management of rheumatoid arthritis (RA) with traditional and biologic disease-modifying antirheumatic drugs (DMARD) in 2 parts. Part II, focusing on specific safety aspects of treatment with traditional and biologic DMARD in patients with RA, is reported here. Methods. Key questions were identified a priori based on results of a national needs-assessment survey. A systematic review of all clinical practice guidelines and consensus statements regarding treatment with traditional and biologic DMARD in patients with RA published between January 2000 and June 2010 was performed in Medline, Embase, and CINAHL databases, and was supplemented with a grey literature search including relevant public health guidelines. Systematic reviews of postmarketing surveillance and RA registry studies were performed to update included guideline literature reviews as appropriate. Guideline quality was independently assessed by 2 reviewers. Guideline characteristics, recommendations, and supporting evidence from observational studies and randomized trials were synthesized into evidence tables. The working group voted on recommendations using a modified Delphi technique. Results. Thirteen recommendations addressing perioperative care, screening for latent tuberculosis infection prior to the initiation of biologic DMARD, optimal vaccination practices, and treatment of RA patients with active or a history of malignancy were developed for rheumatologists, other primary prescribers of RA drug therapies, and RA patients. Conclusion. These recommendations were developed based on a synthesis of international RA and public health guidelines, supporting evidence, and expert consensus in the context of the Canadian health system. They are intended to help promote best practices and improve healthcare delivery for persons with RA. (First Release June 15 2012; J Rheumatol 2012;39:1583-602; doi:10.3899/jrheum.120165)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available